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Objective. Inﬂammation plays a key role in the pathophysiology of abdominal aortic aneurysms (AAAs). Newly discovered
Sphingosine-1-Phosphate Receptors (S1P receptors) are critical in modulating inﬂammatory response via prostaglandin
production. The aim of the current study was to investigate the expression of diﬀerent S1P receptors in AAAs and compared
with normal aortas at the protein level. Materials and Methods. Aortic specimens were harvested during aortic reconstructive
surgery for the AAA group or during organ transplant for the control group. The protein expression of S1P1, 2 and 3 in AAAs and
normal aortas was assessed by Western blotting and immunohistochemical analysis. Results. There were 40 AAAs and 20 control
aortas collected for the receptor analysis. For Western blot analysis, S1P1 expression was not detected in either group; S1P2 protein
was constitutively detected in both types of aortas but its expression level was signiﬁcantly decreased by 73% (P<0.05) in AAAs
compared with the control group. In contrast, strong S1P3 expression was detected in AAAs aortas but not in normal aortas.
Immumohistochemical staining showed similar results, except a weak S1P3 signal was detectable in normal aortas. Conclusions.
Western blot and staining results consistently showed the down-regulation of the S1P2 protein with simultaneous up-regulation
of the S1P3 protein in AAAs. Since those newly discovered receptors play an important role in the inﬂammatory cascade, the
modulating of S1P signaling, particularly via S1P2 and S1P3, could represent novel therapeutic targets in future AAA treatments.
1.Introduction
Abdominal aortic aneurysm (AAA) is the localized dilation
of the infrarenal aorta. If surgical treatment is not applicable,
an AAA progresses to rupture with a high mortality rate
and causes 1%–3% of elderly male deaths in developed
countries each year [1]. Analysis of the aneurysmal wall has
demonstrated that connective tissue degradation, increased
atherosclerosis, and chronic inﬂammation are the common
pathological features of AAAs [1–3].
Sphingosine-1-phosphate (S1P) is a newly discovered
low-molecular-weight zwitterionic lysophospholipid mole-
cule that is generated from the metabolism of sphingomyelin
by a series of enzymes including sphingosine kinase, S1P
phosphatase, and S1P lyase in mammals [4]. The main
sources of S1P are platelet cells in plasma, while other cell
types such as erythrocytes, neutrophils, and mononuclear
cells can also produce and release S1P upon activation
[4, 5] .S 1 Pe x e r t saw i d er a n g eo fp h y s i o l o g i c a la c t i v i t i e s ,
particularly inﬂammatory reactions through the interactions
withﬁvediﬀer entr ec ept orsubtypes1,2,3,4,and5.Theyar e
the members of the endothelial diﬀerentiation gene family of
G protein-coupled receptors [4], and diﬀerential expressions
of S1P receptors are thought to modulate the cellular
inﬂammatory response [6]. A precise S1P/S1P receptor
balance is found to be responsible for the signaling of cell
growth and regulation of cell metabolism in mammal [7, 8].
An imbalance of this system also participates in pathologic
conditions such as cancer and inﬂammatory diseases [9, 10].
S1P2 is the major expressed S1P receptor, while S1P1 or
S1P3 is only weakly expressed in healthy vascular endothelial
cells [11] and vascular smooth muscle cells (VSMCs) [12].
Consistently with this receptor multiplicity and pleiotropic
signaling mechanisms, S1P receptors inﬂuence numerous
cell functions. Particularly, diﬀerential expressions of S1P
receptors have been demonstrated to either promote or
inhibit the inﬂammatory inﬁltration in diverse cell types
by inducing cyclooxygenase 2 (COX-2) expression [6]2 Mediators of Inﬂammation
with subsequent prostaglandin E2 (PGE2) or prostacyclin
(PGI2)p r o d u c t i o n[ 13–15]. Our previous study showed that
inﬂammatory mediators such as Cox-2 and prostaglandin
E2 are also widely expressed in AAA explants [16]. Those
phenomena implicating S1P receptors may play some roles
in the pathogenesis of AAA.
S1P1, S1P2, and S1P3 receptors are the major S1P recep-
tor subtypes in the vascular system [11, 12]. However, the
expressions of these three S1P receptors in AAA remain
unknown. In the present study, we aimed to investigate the
S1P1, 2 and 3 receptor protein expressions in AAAs and
compare them with healthy aortas.
2.MaterialsandMethods
2.1. Human Abdominal Aorta Tissues Collection. Cross-sec-
tions of aneurysm wall, which were dissected of luminal
thrombus, were removed from the AAA patients who under-
went open surgical aneurysmal repair in a local hospital.
Control aortic tissues were obtained from the corresponding
location of healthy organ donors without known cardio-
vascular diseases and connective tissue disorders during
the transplant operation. Aneurysmal patients with the
Marfan syndrome and other connective tissue disorders were
excluded from this study.
Each collected specimen was thoroughly washed with
normal saline solution, and then the tunica intima elimina-
tion procedure was conducted using a scalpel and forceps.
All specimens were divided into two parts for the western
blotting which was kept in a −80◦Cf r e e z e ra n di m m u n o -
histochemical analysis, respectively.
All experiments were performed with the approval from
the local institution’s ethics committee. Informed consent
was obtained from AAA patients and organ donors’ relatives.
2.2. Western Blot Analysis. Frozen tissues were ﬁrst thawed
and then lysed with cell lysis buﬀer (Cell Signaling. Tech-
nology, Danvers, MA, USA) containing protease inhibitor
(Roche, Basel, Switzerland). The protein concentration of
each specimen was measured based on the Bradford method
utilizing the Bio-Rad Protein Assay Kit (Bio-Rad Laborato-
ries, Hercules, CA, USA) with bovine serum albumin (BSA)
as the standard. After the protein denaturing procedure with
loading buﬀer (pH 6.8 24mM Tris-HCl, 684mM glycerol,
14mM SDS, 142mM beta-mercaptoethanol, 0.3mM bro-
mophenol blue), each sample (50µg) was resolved on 12%
SDS-polyacrylamide gel electrophoresis (PAGE) gel (Bio-
Rad Laboratories) at room temperature then transferred
onto a polyvinylidene ﬂuoride (PVDF) membrane (Bio-
Rad Laboratories) at 4◦C. After blocking in 10% TBS–
0.01% Tween 20 (TBST) diluting nonfatty milk (Bio-Rad
Laboratories) for two hours at room temperature, the
membranes were then incubated overnight at 4◦Cw i t h
primary antibodies against S1P1 receptor (Catalogue no.
sc-48356, dilution 1:100, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or S1P2 receptor (Catalogue no. sc-25491,
dilution 1:200, Santa Cruz Biotechnology) or S1P3 recep-
tor (Catalogue no. sc-30024, dilution 1:100, Santa Cruz
Biotechnology) with GAPDH (1:1000, Cell Signaling Tech-
nology) as the positive control. After membrane washing
using TBST solution, HRP-conjugated goat anti-mouse
(1:2000) or goat anti-rabbit (1:4000) secondary antibody
(Dako, Glostrup, Denmark) was added and the membranes
were then incubated for 1 hour at room temperature. After
washing, signals were visualized by luminol reagents (Bio-
Rad Laboratories) and the densitometry of each exposing
blotting was analyzed by ImageJ 1.44 software (National
Institutes of Health, Bethesda, MD, USA). The relative
expression of the studied receptors’ protein was calculated by
the detected signal divided by the internal positive control
(GAPDH) expression signal in each sample.
2.3. Immunohistochemical Study. The staining procedure
was performed on paraﬃn-embedded aortic tissue (5µm)
sections accordingto the manufacturer’sinstructions (Dako-
Cytomation EnVision + System-HRP (DAB) Kit (Dako)).
Speciﬁcity of S1P receptor antibodies was ﬁrstly validated
by positive and negative tests using healthy adult rat brain
paraﬃn sections. Brieﬂy, all sections were antigen retrieved
with boiling sodium citrate buﬀer (pH 6) and incubated
with either mouse anti-S1P1 receptor antibody (1:25),
rabbit anti-S1P2 receptor antibody (1:100), or rabbit anti-
S1P3 receptor antibody (1:100) (Santa Cruz Biotechnology)
overnightat4◦C.Afterstaining,allspecimensweresubjected
to the dehydration procedure and sealed for microscopy
observation.
To avoid staining underestimation due to considerable
regional variations, 5 continuous × 200 microscopy views
of each stained specimen, which had the largest amount
of positive stained VSMCs, were captured and recorded
(Nikon, Tokyo, Japan). Two researchers scored the positive
immunostaining using the scoring system according to
the Wang and colleagues study [17]. Brieﬂy, a proportion
subscore from 0 to 4 (i.e., 0—0% positive stained, 1—1%–
25% positive stained, 2—26%–50% positive stained, 3—
51%–75% positive stained, 4—76%–100% positive stained)
and an intensity subscore from 0 to 3 (i.e., 0: no staining,
1: weak staining, 2: moderate staining, 3: intense staining)
wereﬁrstassignedbyeachobserverforeachslide.Aweighted
score was then determined by multiplying the proportion
subscore and the intensity subscore. Finally, a mean value of
the ﬁve weighted scores for each specimen was calculated.
2.4. Statistical Analysis. All data were expressed as means ±
SD. Statistical analysis was performed by SPSS 18.0 software
(SPSS, Chicago, IL, USA). Any statistical diﬀerences between
the two groups’ experimental results were determined by
independent sample t-tests. Correction for ages and sex of
patients on receptor expression levels were made using a
linear model. A P value < 0.05 was considered as statistically
signiﬁcant.
3. Results
3.1. Patient Characteristics. There were 40 AAA specimens
and 20 control aortas obtained from the correspondingMediators of Inﬂammation 3
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Figure 1: Representative pictures of western blot analysis of S1P
receptors in AAA and control aortic tissues. S1P1 expression was
undetectable in both AAA and normal aortas, while it became
detectable in rat brain tissues (a). Expression level of S1P2 protein
was signiﬁcantly decreased in AAAs compared with control aortas
(b). S1P3 expression was detectable in AAAs only (c). GAPDH
antibody was used as internal positive control in each WB
experiment.
surgical patients and organ donors. Most of patients were
male, and the control patients were younger than the AAA
patients. Patient characteristics are listed in Table 1.
3.2. Western Blot Analysis. S1P1 receptor protein (38kDa)
w a su n d e t e c t a b l ei nb o t ht i s s u e s( Figure 1(a)). For S1P2
receptor protein (45kDa), positive signals were detected
in both AAA and control aortic tissues, with AAA tissues
had a signiﬁcantly lower protein expression level compared
with control aortas (Figure 1(b)). In contrast, S1P3 receptor
protein (45kDa) was highly expressed in AAA aortas but was
undetectable in control aortas (Figure 1(c)).
TherelativeintensitiesofS1P1and2receptorsexpression
by western blot analysis are shown in Figure 2 upper and
lower panels, respectively. The protein level of S1P2 receptor
was decreased by 73% (P<0.05) in the AAA tissues (mean
relative intensity of 0.29) compared with the control aortic
tissues (mean relative intensity of 1.08). S1PR3 protein levels
were signiﬁcantly upregulated in AAA tissues with average
relative intensity of 0.65, whereas it was undetectable in
normal aortas.
S1PR2 protein levels detected by
western blot experiments
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Figure 2: Quantitative analysis of S1P2 (upper panel) and 3
(lower panel) protein expression levels in western blot analysis. The
relative S1P2 protein level was decreased by 73% (P<0.05) in
AAAs (relative expression intensity of 0.29) compared with normal
aortas (relative expression intensity of 1.08). S1PR3 protein levels
were signiﬁcantly upregulated in AAA tissues with average relative
intensity of 0.65, whereas it was undetectable in normal aortas.
3.3. Immunohistochemical Staining Analysis. S1P1 receptor
expression level was undetectable in both AAA (a) and
normal aortas (b), as shown in Figure 3.AP o s i t i v ec o n -
trol of S1P1 receptor was performed in healthy adult
rat brain for validating its speciﬁcity (Figure 3(c)). S1P2
receptor protein was expressed in both types of aortas,
with pronounced S1P2 receptor staining observed in control
aortas (Figure 4). S1P3 receptor protein was found in the
AAA tissues (Figure 5(a)), but it was almost undetectable
in normal aortas (Figure 5(b)). The staining scores of both
types of tissues sections are shown in Table 2.
Positive staining of S1P2 and S1P3 receptors in the
aortic walls showed that they were localized in VSMC
plasma membrane and cytoplasm but absent in the nucleus
(Figures 4 and 5).4 Mediators of Inﬂammation
Table 1: Patient characteristics of AAA patients group and control group.
AAA group (n = 40) Control group (n = 20)
Age (mean age ± SD) 70.08 ±9.72yrs 42.05 ±13.55yrs
Gender (male %) 95% 40%
Smoking (%) 67.5% —
Hypertension (%) 65% 5%
Diabetes (%) 7.5% 0%
Cardiac disease (%) 45% 0%
Renal disease (%) 27.5% 5%
(a) (b)
(c)
Figure 3: Representative staining pictures of S1P1 protein in AAA
(a), control aortic (b) sections, and healthy adult rat brain paraﬃn
sections (c) (×200). S1P1 protein was undetectable in both types of
tissues.
Table 2: Staining scores of immunohistochemical analysis of S1P
receptors in both types of tissues.
AAA group (n = 40) Control group (n = 20)
Mean staining score (range)
S1P1 receptor — —
S1P2 receptor 2.4 (0.6–4.8) 8.3 (5.2–10.8)
S1P3 receptor 5.2 (0.6–10.6) 0.25 (0–0.8)
3.4. Correction for Ages and Sex. Giving the age and sex
discrepancy existed in the patients, corrections for ages
and sex of the receptor protein expressions was made. The
association between S1P2 and S1P3 protein (both IHC
and WB expression levels) in the patients were robust to
correction in a linear model with age and sex (P<0.008).
4. Discussion
Among the studied S1P receptors, only S1P2 and S1P3
receptor proteins werediﬀerentiallyexpressed inAAA tissues
(a)
(b)
Figure 4: Representative staining pictures of S1P2 in AAAs and
control aortic sections (×200). S1P2 protein was more pronounced
in the normal aortas (b) than that in the AAAs (a).
compared with the control aortas, while S1P1 receptor
protein was absent in both types of tissues. Diﬀerential
S1P receptors expressions have been shown to participate
in diverse physiological processes, such as cell survival
and apoptosis [18], and pathological processes, such as
angiogenesis, inﬂammation, cancerogenesis, and immune
regulation [9]. Inﬂammation is one of the common patho-
logical features of AAAs [3]. Thus, the present novel
ﬁndings may implicate the importance of these receptors inMediators of Inﬂammation 5
(a)
(b)
Figure 5: Representative staining pictures of S1P3 in AAA and
control aortic sections (×200). More S1P3 protein was found in
the AAA (a) than that in the normal aortas, in which it was almost
undetectable.
the inﬂammation attribute to AAA pathogenesis. Neverthe-
less, atherosclerosis is indeed regarded as a chronic inﬂam-
matory disease with atherosclerotic plaques containing
inﬂammatory inﬁltrates, which implicated in the formation
of AAA [19]. Thus, the possibility of S1P receptor expression
related to the atherosclerotic event cannot be excluded.
S1P1 receptor is undetectable in both types of aortic
tissues. Other researchers found that only some speciﬁc cell
types, such as endothelial cells, cardiomyocytes, neural stem
cells, as well as B cells, and T cells, express marked S1P1
[4]. Healthy rat adults’ VSMCs express S1P1 receptor weakly
[20], and the deletion of S1P1 receptor is embryonically
lethalsinceitcausesthefailureofdorsalmigrationofVSMCs
to form the tunica media layer of arteries [21], suggesting
thatS1P1receptorshouldbecriticalinvasculardevelopment
rather than in maintaining VSMCs metabolism [21]. A more
recentstudysuggestedthatS1P1isinvolvedinthephenotype
regulation of adult smooth muscle cells [22]. They utilized
a rat carotid artery balloon injury model and demonstrated
that there was a transient over expression and activation of
S1P1 receptor after injury. This action can facilitate VSMCs
transfer into the proliferative and migratory phenotype.
However, such S1P1 receptor over expression will be restored
to the basal value by 7 days after injury, suggesting that
this irritable S1P1 receptor activation may be a short-term
injury response. Thus, we postulated that the S1P1 receptor
protein may be transiently increased during early AAA
lesion, but its high expression will subsequently return to
the basal level or become undetectable at the advanced stage
of AAA development. In addition, S1P1 receptor is possibly
responsible for the development of circulation system and
expressed in the endothelial cells, rather than expressed in
smoothmusclecellsinmatureaortas[21]whichmayexplain
for absent of S1P1 levels in the late stages of aneurysm.
S1P2receptorproteinwasdetectedinbothtypesofaortic
tissues, particularly in control aortas. Indeed, S1P2 receptor
has been previously shown to be the major S1P receptor
expressing population in a wide variety of tissues in humans,
like vascular endothelial [11] and smooth muscle cells [12],
butnotininﬂammatoryinﬁltrates[9].Thisparticularrecep-
tor can facilitate VSMCs’ contractile phenotype expressions
and negatively regulate their proliferation and migration
[22]. Moreover, S1P2 receptor is capable of inducing Cox-
2 expression and producing prostacyclin (PGI2)i nr e s p o n s e
to exogenous S1P stimulus [15, 23, 24]. PGI2 possesses anti-
inﬂammatory functions and simultaneously relaxes VSMCs
and suppresses their proliferation and migration [25]. Thus,
thedecreasedexpressionofanti-inﬂammatoryS1P2receptor
in VSMCs of AAAs, and probably not expressed in the
inﬂammatory inﬁltrates, may impair the production of
PGI2 and ultimately lead to the pronounced inﬂammation
response in AAA patients [16]. Therefore, the S1P2 receptor
downregulation of VSMCs is obviously an important etio-
logical factor in AAA development.
Markedly S1P3 receptor protein was found in AAA
tissues. S1P3 receptor possesses a promoting inﬂamma-
tory response property as it can induce Cox-2 expression
and concomitant PGE2 production in various cell types
[13, 14, 26, 27]. As a pronounced inﬂammatory inﬁltrate,
PGE2 was also found in AAA explants in our laboratory
previously [28] though the extent of its involvement in
vascular inﬂammation is still unclear. In addition, a very
recent study suggested that S1P3 mediates the chemotactic
eﬀect of its ligand-S1P in macrophages in vitro and in vivo,
which plays a crucial role in atherosclerosis by promoting
inﬂammatory monocyte/macrophage recruitment and alter-
ing smooth muscle cell behavior [29]. We suggested that the
S1P3 receptor protein may be critical in the strengthened
inﬂammatory response and thus atheroslcerosis via the
chemotactic property and the PGE2 pathway during AAA
development. However, the causal relationship between
the inﬂammatory cells recruitment and the prostaglandins
needed to be further explored.
In the present study, a weak S1P3 staining signal was
foundinnormalaortas,thoughitbecameundetectableusing
western blot analysis. This staining result was consistent with
Ryu et al. study that S1P3 is found to be weakly expressed in
human healthy VSMCs [12].
Though age and sex discrepancy existed in the studied
patients, the present analysis found that the expression of6 Mediators of Inﬂammation
the S1P2 and 3 receptor proteins are not age and sex depen-
dent. Thus, the up- or downregulated receptor probably
related to the inﬂammatory cascade underlying the AAA
pathogenesis but is not simply a feature of aging or sex
diﬀerence.
The limitation of the present study is only an obser-
vational analysis on surgical aneurysmal aortas. Thus, we
cannot extrapolate the observations to the initiation or
promotion of aneurysm formation. Nevertheless,the present
work has provided evidence that aneurysmal aortic tissue
exhibits a decreased activity of S1P2 and enhanced S1P3
receptor,whichmaycontributetotheinﬂammationofaortic
walls involved in AAA pathology.
Our ﬁndings of the diﬀerential expression of S1P recep-
tors in AAA compared with normal aortas are novel and
may be helpful to delineate the important inﬂammatory
mechanisms in AAA development. This investigation has
provided a new concept in the inﬂammatory response in the
lesions,andtheregulationofS1PreceptorviaS1P2andS1P3
may open a new regime for AAA treatment in the future.
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